Background: Red ginseng is a traditional medicine that has been used to treat numerous
metabolic and inflammatory diseases. Probiotic administration has been established to have beneficial
effects in non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to determine
whether a combination of Korean red ginseng (KRG) and probiotics could synergistically reduce
NAFLD and liver inflammation compared with the effects reported for each individual product.
Method: db/db and C57BL/6 mice were fed a normal chow diet and high-fat diet (HFD), respectively,
and were treated with KRG, probiotics, or both. Samples were examined for lipid content, kinase protein
phosphorylation, and gene expression patterns.
Results: KRG- and probiotic-treated HFD-fed mice exhibited a reduction in body weight and a decrease
in inflammatory cytokine secretion compared with the non-treated control mice. The same
treatment was less successful in improving NAFLD parameters in the db/db mice while the combination
of both products did not enhance their therapeutic potential.
Conclusion: The results of this study indicate that KRG and probiotics administration ameliorated
NAFLD symptoms in a mouse model of dyslipidemia by reducing weight gain and liver inflammation.
Coadministration of both products did not enhance their efficacy, and further research should be conducted
to clarify their mechanisms of action.